TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03462342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.
Study: NCT02011958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: 40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)
Study: NCT03732703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, dexamethasone, ixazomib, pomalidomide
Description: Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study: NCT04098614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Coach Intervention
Description: Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
Study: NCT03462342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT02399618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
Study: NCT03462342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth.
Study: NCT04923165

Intervention type: DEVICE
Intervention: robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical analyses
Description: ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;

Intervention type: DEVICE
Intervention: BIA, hand grip
Description: bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip

Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional assessment, MNA
Description: nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
Study: NCT03165669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscospring PostuRite - medium model
Description: Cervical pillow use, 30-minutes instruction session supported by a brochure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
Study: NCT04050943

Intervention type: OTHER
Intervention: observational cohort
Description: Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
Study: NCT03218150

Intervention type: PROCEDURE
Intervention: cranioplasty
Description: . The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws.

Intervention type: PROCEDURE
Intervention: cranioplasty
Description: . The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws.

Intervention type: PROCEDURE
Intervention: cranioplasty
Description: . The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws.
Study: NCT02913924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04746183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NHS standard of care as per COVID-19 treatment guidelines
Description: NHS standard of care as per COVID-19 treatment guidelines
Study: NCT03103308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Training and Transplant
Description: Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitoring and Transplant
Description: Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
Study: NCT03735979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo solution
Study: NCT02593773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon γ-1b
Description: The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
Study: NCT02396459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triac
Description: Triac, individually titrated dose
Study: NCT02882373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT03732703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study: NCT02626403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT02441686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Study: NCT03965429

Intervention type: OTHER
Intervention: Blood samples (additional tubes from care) longitudinal
Description: Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).

Intervention type: OTHER
Intervention: Blood samples (additional tubes from care) at inclusion
Description: In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.
Study: NCT02176967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06695286

Intervention type: OTHER
Intervention: Multimodal rehabilitation training at high intensity
Description: In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL.

Intervention type: OTHER
Intervention: Multimodal rehabilitation training at low intensity
Description: In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL.